| Paroxysmal nocturnal hemoglobinuria
Ultomiris vs Voydeya
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Ultomiris vs Voydeya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVoydeya has a higher rate of injection site reactions vs Ultomiris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Voydeya but not Ultomiris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ultomiris
Voydeya
At A Glance
IV infusion
Every 4-8 weeks
C5 complement inhibitor
Oral
Three times daily
Complement Factor D inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
- Paroxysmal nocturnal hemoglobinuria
Dosing
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome (5 to <40 kg) Weight-based IV loading dose (600-1,200 mg), followed by weight-based maintenance dose every 4 weeks (5 to <20 kg) or every 8 weeks (20 to <40 kg), starting 2 weeks after loading dose.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (>=40 kg) Weight-based IV loading dose (2,400-3,000 mg), followed by weight-based maintenance dose (3,000-3,600 mg) every 8 weeks, starting 2 weeks after loading dose.
Paroxysmal nocturnal hemoglobinuria 150 mg orally three times a day as starting dose; may increase to 200 mg three times a day if hemoglobin has not increased by >2 g/dL after 4 weeks, if transfusion was required in the previous 4 weeks, or based on clinical judgment.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Unresolved serious infection caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae type B
Adverse Reactions
Most common (>=10%) Upper respiratory tract infection, headache, diarrhea, nausea, vomiting, hypertension, pyrexia, back pain, arthralgia, COVID-19
Serious Meningococcal infections, other infections (including fatal COVID-19 pneumonia and sepsis), infusion-related reactions
Postmarketing Anaphylaxis, cholestatic or mixed pattern liver injury with increased serum liver enzymes and bilirubin
Most common (>=10%) Headache
Serious Pancreatitis, cholecystitis, blood bilirubin increased
Pharmacology
Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds complement protein C5 with high affinity, preventing its cleavage to C5a (proinflammatory anaphylatoxin) and C5b (initiating subunit of the membrane attack complex), thereby inhibiting MAC formation and terminal complement-mediated tissue damage in PNH, aHUS, gMG, and NMOSD.
Complement Factor D inhibitor; danicopan binds reversibly to Factor D and selectively inhibits the alternative complement pathway, preventing C3 convertase formation, reducing C3 fragment opsonization, and thereby controlling extravascular hemolysis in PNH when used as add-on therapy to a terminal complement inhibitor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ultomiris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Voydeya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Ultomiris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Voydeya
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Ultomiris
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Voydeya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Ultomiris.
$0
Alexion OneSourceCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
UltomirisView full Ultomiris profile
VoydeyaView full Voydeya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.